Skip to content

Mood Stabilizer-induced Metabolic Abnormalities in Bipolar Disorder

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04486092
Enrollment
200
Registered
2020-07-24
Start date
2015-02-28
Completion date
2021-07-31
Last updated
2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Brief summary

The potential effects of microbiota in bipolar disorder (BD) with microbiota-related dysfunction have not yet been explored clinically, and the integration of microbiota and pharmacometabolomic approaches can provide us the identification of the significant effects of mood stabilizers on metabolic homeostasis, treatment response, and cognitive performance. Therefore, we propose to develop the integration of the microbiota and pharmacometabolomics knowledge base about the mood stabilizer-induced metabolic abnormalities in BD patients.

Interventions

DRUGValproic Acid

Sponsors

National Cheng-Kung University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Bipolar disorder outpatients (aged 18-65 years) who meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) diagnostic criteria and start to receive valproate (VPA) will be enrolled consecutively by trained psychiatrists.

Exclusion criteria

* Exclude are patients who had DSM-V diagnosis for substance abuse within the past three months * Had treated with antibiotics and/or functional foods (probiotics and/or prebiotics) for at least one month before entering study * Presence of stomach/gut problems such as chronic diarrhea, constipation, gas, heartburn, bloating, etc. * Had an organic mental disorder, mental retardation, dementia, or other diagnosed neurological illness * Had a surgical condition or a major physical illness * Were pregnant or breast-feeding * Had any concomitant DSM-V Axis I diagnoses together with somatic or neurologic illnesses interfering psychiatric evaluation.

Design outcomes

Primary

MeasureTime frame
Gut microbiota composition12 weeks

Secondary

MeasureTime frame
Metabolic syndrome12 weeks

Countries

Taiwan

Contacts

Primary ContactHui-Hua Chang, Ph.D.
huihua@mail.ncku.edu.tw886-6-2353535

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026